Journal of Pharmaceutical Practice and Service 2022;40(5):422-426

doi:10.12206/j.issn.2097-2024.202111034

Advances in antidepressant therapy related to gut microbiota

Qiannan WANG 1 ; Xinhui HUANG 1 ; Minxu YANG 1 ; Xingrui YANG 1 ; Kehan ZHU 1 ; Tingting ZHOU 2

Affiliations

+expand

Keywords

depression; gut microbiota; microbiome-gut-brain axis

Country

China

Language

Chinese

Abstract

Objective This paper introduces the research progress on the pathogenesis of depression related to gut microbiota and provides the resources for the subsequent development of antidepressant drugs targeting gut microbiota. Methods 33 literatures on gut microbiota and depression in recent years were reviewed. The changes of gut microbiota diversity under depression were discussed from the perspectives of phylum, family and genus. The relationship between gut microbiota and the pathogenesis of depression was expounded at the molecular level, and the existing relevant studies were summarized. The feasibility of drug development targeting gut microbiota was explored. Results There is a relationship between gut microbiota disorder and depression. Existing biological agents such as probiotics can alleviate depression by adjusting the disorder of gut microbiota. Conclusion The imbalance of gut microbiota is closely related to the occurrence of depression, and the development of drugs targeting gut microbiota may become a new way to treat depression.